Mesothelioma is an aggressive and usually fatal form of cancer. Often associated with asbestos exposure, mesothelioma takes decades to develop but can claim someone’s life in a matter of years after their diagnosis.
Currently, researchers are in the early stages of developing working treatments for mesothelioma. Most patients will undergo treatment to extend their life expectancy and improve their quality of life in the months following their diagnosis.
Most forms of mesothelioma treatment currently available are more palliative than curative. However, an immunotherapy drug going into a new stage of clinical trial has shown real promise for extending the lives of those diagnosed with mesothelioma.
What research shows about ONCOS-102 so far
According to a press release supplied by Targovax, the manufacturer of ONCOS-102, this specialized drug almost doubles how long those diagnosed with mesothelioma survive after starting treatment. The median overall survival for those with mesothelioma while undergoing just chemotherapy was 13.5 months in their study.
However, those who received ONCOS-102 in conjunction with traditional chemotherapy treatments survived between 21.9 and 25 months after beginning treatment. Researchers followed the patients for 24 months after the end of treatment to assess the impact of the medication on their condition and their survival. The medication seems to help the immune system’s response to the presence of mesothelioma in the body, which could eventually lead to even more successful treatment options.
Learning about various advances in medical options for those with mesothelioma can help you get the care you need or convince a loved one to seek out compensation to cover the cost of medical treatment not covered by standard health insurance programs.
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:”Times New Roman”,serif;}